RecruitingPhase 1NCT05142189
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
Studying Autosomal anomaly syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BioNTech SE
- Principal Investigator
- BioNTech Responsible PersonBioNTech SE
- Intervention
- BNT116(biological)
- Enrollment
- 320 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2022 – 2031
Study locations (30)
- University of Kentucky Chandler Medical Center, Lexington, Kentucky, United States
- Norton Cancer Institute, Louisville, Kentucky, United States
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, United States
- MD Anderson Cancer Center, Houston, Texas, United States
- NEXT Virginia, Fairfax, Virginia, United States
- Scientia Clinical Research, Randwick, New South Wales, Australia
- Royal North Shore Hospital, Sydney, New South Wales, Australia
- Cancer Research SA, Adelaide, South Australia, Australia
- Monash Health, Clayton, Victoria, Australia
- Universitätsklinikum Köln, Cologne, Germany
- Krankenhaus Nordwest GmbH - Institut Fuer Klinisch-Onkologische Forschung (IKF), Frankfurt, Germany
- University Medical Center Hamburg-Eppendorf, Hamburg, Germany
- Universitaetsmedizin der Johannes Gutenberg Universitaet Mainz KoeR, Mainz, Germany
- ICON-PRA Budapest, Fázis 1 Vizsgálóhely, Budapest, Hungary
- Semmelweis Egyetem ÁOK Belgyógyászati és Onkológiai Klinika, Budapest, Hungary
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05142189 on ClinicalTrials.gov